KEYTRUDA: Uses, Dosage, Administration and Side Effects

KEYTRUDA is an important immunotherapy medicine used to treat several types of cancer. It contains the active ingredient pembrolizumab, a monoclonal antibody that works by helping the immune system recognize and attack cancer cells.

If you are looking for KEYTRUDA or need assistance obtaining the treatment, Biological Medicines Supply and Integrated Care Group provides medicine supply and hand-to-hand delivery services in Egypt and several Arab countries. For inquiries, contact 01003540816. Working hours are from 2 PM to 10 PM.

What is KEYTRUDA?

KEYTRUDA is the brand name for Pembrolizumab, an immunotherapy medicine that belongs to a group of monoclonal antibodies.

Pembrolizumab targets a receptor called PD-1, which is found on certain immune cells. By blocking this pathway, pembrolizumab may help the immune system recognize cancer cells and attack them.

Unlike conventional chemotherapy, KEYTRUDA works by activating an immune response against cancer cells rather than directly targeting rapidly dividing cells.

What is KEYTRUDA used for?

KEYTRUDA is used to treat several types of cancer. Depending on the type of cancer and the patient's condition, it may be used alone or in combination with other cancer treatments.

KEYTRUDA is used in certain cases of:

• Non-small cell lung cancer.
• Melanoma.
• Certain head and neck cancers.
• Kidney cancer.
• Certain bladder and urinary tract cancers.
• Certain colorectal cancers.
• Certain stomach and esophageal cancers.
• Certain cervical cancers.
• Other types of cancer depending on tumor characteristics and medical test results.

This does not mean that KEYTRUDA is suitable for every cancer patient. Its use depends on the type and stage of cancer, tumor characteristics, test results, and the patient's overall medical condition.

How does KEYTRUDA work?

The principle behind pembrolizumab immunotherapy is to help the body's immune system fight cancer.

Some cancer cells can use the PD-1/PD-L1 pathway to reduce the immune system's ability to attack them. Pembrolizumab blocks the PD-1 receptor, which may help immune cells recognize and attack cancer cells.

This mechanism is one of the main differences between KEYTRUDA immunotherapy and conventional chemotherapy.

Is KEYTRUDA a chemotherapy treatment?

No. KEYTRUDA is not conventional chemotherapy. It is an immunotherapy medicine.

However, doctors may prescribe KEYTRUDA together with chemotherapy or other cancer treatments in certain cases, depending on the type of cancer and the patient's treatment plan.

Therefore, the fact that KEYTRUDA is an immunotherapy does not mean that it cannot be combined with chemotherapy.

How is KEYTRUDA administered?

KEYTRUDA is administered through an intravenous IV infusion by a doctor or qualified healthcare professional.

The infusion usually takes approximately 30 minutes, while the number of doses and the interval between treatments depend on the type of cancer, prescribed dose, and treatment plan.

Patients should not determine their own KEYTRUDA dose or change the treatment schedule without consulting their oncologist.

What is the appropriate KEYTRUDA dosage?

The KEYTRUDA dosage varies depending on the type of cancer, the treatment regimen, the patient's age and medical condition, and other factors determined by the treating physician.

There is no single dosage that is appropriate for every patient.

For this reason, KEYTRUDA should only be administered according to the prescription and treatment plan established by an oncologist.

What are the side effects of KEYTRUDA?

Like all medicines, KEYTRUDA may cause side effects, and these can vary from one patient to another.

Because KEYTRUDA activates the immune system, it can sometimes cause the immune system to attack healthy tissues or organs.

Possible side effects include:

• Fatigue.
• Skin rash or itching.
• Diarrhea.
• Nausea.
• Muscle or joint pain.
• Cough.
• Shortness of breath.
• Changes in thyroid function.
• Changes in liver function.

KEYTRUDA can also cause immune-related reactions that may affect different organs of the body. Therefore, any new, unusual, or worsening symptom should be reported to the treating physician.

When should you contact your doctor?

Patients should contact their doctor promptly if they experience severe or unusual symptoms while receiving KEYTRUDA, especially symptoms that could indicate an immune-related reaction.

These may include:

• New or worsening shortness of breath or cough.
• Severe or persistent diarrhea.
• Severe abdominal pain.
• Yellowing of the skin or eyes.
• Noticeable changes in the amount of urine.
• Severe or unusual weakness.
• Severe or worsening skin rash.

Some immune-related side effects may occur during treatment or even after treatment has ended. Patients should therefore inform any healthcare professional treating them that they are receiving or have previously received KEYTRUDA.

KEYTRUDA, pregnancy and breastfeeding

Patients should inform their doctor before treatment if they are pregnant or planning to become pregnant, because pembrolizumab may cause harm to the fetus.

Contraception and breastfeeding should also be discussed with the treating oncologist before and during treatment and afterward, according to the patient's individual treatment plan.

Patients should not make decisions regarding pregnancy or breastfeeding during treatment without consulting their healthcare provider.

Why should KEYTRUDA be obtained from a reliable source?

KEYTRUDA is an important biological medicine used in cancer treatment, so it is important to obtain it from a reliable source and ensure that the medicine is handled, transported, and stored according to its specific requirements.

KEYTRUDA should only be used with a valid prescription and according to a treatment plan established by a qualified oncologist.

KEYTRUDA Supply with Biological Medicines Supply and Integrated Care Group

Biological Medicines Supply and Integrated Care Group provides medicine supply and delivery services for patients in several countries, with the option to inquire about treatment availability and delivery procedures.

🇪🇬 Egypt

• Coverage across all governorates.
• Direct hand-to-hand delivery to the patient.
• Under approved medical supervision.
• 📞 01003540816
• 🕘 Working hours: 2 PM to 10 PM.

🌍 Sudan and the Arab World

Services include:

• Sudan.
• Saudi Arabia.
• United Arab Emirates.
• Yemen.

Hand-to-hand delivery is available according to the applicable approved procedures.

🕙 Consultation hours: 10 AM to 10 PM.

Conclusion

KEYTRUDA is an immunotherapy medicine containing the active ingredient Pembrolizumab. It is used in the treatment of several types of cancer according to specific medical criteria related to the type and characteristics of the tumor and the patient's condition.

The KEYTRUDA dosage, administration schedule, and number of treatment sessions vary from one patient to another. The treating oncologist must determine the appropriate treatment plan based on the patient's diagnosis and medical test results.

If you are looking for KEYTRUDA or would like to inquire about treatment availability, you can contact Biological Medicines Supply and Integrated Care Group at 01003540816.

Medical disclaimer: This article is intended for educational purposes only and does not replace consultation with an oncologist. Do not start treatment, change the dosage, or stop KEYTRUDA without consulting your treating physician.